The effectiveness of messenger RNA (mRNA) vaccines, especially those designed for
COVID-19, relies heavily on sophisticated delivery systems that ensure efficient delivery of …

Lipid nanoparticles (LNPs) have recently emerged as one of the most advanced
technologies for the highly efficient in vivo delivery of exogenous mRNA, particularly for …

The success of lipid nanoparticles (LNPs) in treating COVID-19 promotes further research of
mRNA vaccines for cancer vaccination. Aiming at overcoming the constraints of currently …

The recent success of mRNA vaccines in SARS-CoV-2 clinical trials is in part due to the
development of lipid nanoparticle delivery systems that not only efficiently express the …

There has been increased interest in the development of RNA-based vaccines for protection
against various infectious diseases and also for cancer immunotherapies. Rapid and cost …

Lipid nanoparticle (LNP) formulations of messenger RNA (mRNA) have demonstrated high
efficacy as vaccines against SARS-CoV-2. The success of these nanoformulations …

mRNA, as one of the foci of biomedical research in the past decade, has become a
candidate vaccine solution for various infectious diseases and tumors and for regenerative …

Vaccine development is among the critical issues for ceasing the COVID-19 pandemic. This
review discusses the current usage of biomaterials in vaccine development and provides …

The world raced to develop vaccines to protect against the rapid spread of SARS-CoV-2
infection upon the recognition of COVID-19 as a global pandemic. A broad spectrum of …

Lipidic carriers are composed of natural, synthetic, or physiological lipid/phospholipid
materials. The flexibility of lipid-based delivery systems for transferring a variety of molecules …